# Antigen Receptors and Checkpoints

> How does a receptor with no enzyme and almost no tail switch on a T cell, and what keeps that cell from attacking healthy tissue? This lesson follows the first minute after an antigen receptor finds its target, from two phosphates on a short motif to three pathways you already know, then the second signal and two of the brakes, CTLA-4 and PD-1. Afterwards you will be able to explain how checkpoint antibodies and engineered CAR T cells follow from the wiring.

Course: Cell Signaling (Signals that build and defend an animal). Level: advanced university and graduate. About 15 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/antigen-receptors-and-checkpoints/

Builds on: Phosphorylation: Kinases and Phosphatases · Protein Modules: SH2, SH3, PTB, PDZ and PH · Adaptors, Docking Proteins and Scaffolds

## What you'll learn

- Describe an antigen receptor as recognition chains with almost no tail joined to partner chains whose tails carry ITAMs.
- Trace the first minute of T-cell activation from Lck and ZAP-70 through LAT to the calcium, PKC and Ras branches.
- Explain why a T cell needs a second signal through CD28, and what the brakes CTLA-4 and PD-1 each do.
- Explain how checkpoint-blocking antibodies and chimeric antigen receptors follow from this wiring, and name a risk of each.

**The receptor that tells a T cell it has found an infected cell has a tail inside the cell only a few amino acids long, with no enzyme anywhere in it.** It is not a kinase, and unlike the cytokine receptors in [JAK-STAT signalling](https://stemhop.com/lessons/jak-stat) its own chains do not even hold one. So how does it signal, and what keeps a cell that is armed to kill from attacking healthy tissue? The answers became two kinds of cancer treatment.

## The idea: one set of chains recognises, another set signals

A T cell is a white blood cell that inspects the surfaces of other cells. An antigen is whatever its receptor recognises: for most T cells, a short peptide held in the groove of a major histocompatibility complex (MHC) protein, a display molecule on the surface of another cell. The T-cell receptor is a pair of chains, alpha and beta, whose outer tips differ from one T cell to the next.

The receptor’s sequence took years to find, because a T cell releases none of it to purify in quantity. In March 1984 the laboratories of Tak Mak in Toronto and Mark Davis at the NIH and Stanford reported the gene for one of its chains in one issue of *Nature*, and the predicted protein resembled an antibody chain. Two months later Yueh-hsiu Chien, with Davis, showed that the gene is cut and rejoined in T cells, as antibody genes are in B cells, the white blood cells that make antibodies.

The puzzle was on the inside: no kinase, and no catalytic domain of any kind. The receptor travels with partner chains (CD3 gamma, delta and epsilon, and a chain called zeta), which the receptor needs in order to reach the surface.

In 1989 Michael Reth published a short letter in *Nature* that contained no experiment. He had lined up published tail sequences of partner chains, among them zeta, CD3 gamma and delta, the chain then called MB-1 (now Ig-alpha) of the B-cell receptor, and two chains of the mast-cell IgE receptor. All shared one pattern, written here in the form used today:

> **Y-x-x-(L or I), then 6 to 8 residues, then Y-x-x-(L or I)**

Here x is any amino acid. Reth proposed that, once receptors were cross-linked, the conserved residues from several chains would come together to form a binding site for the proteins that start the signal. The pattern is now called an ITAM (immunoreceptor tyrosine-based activation motif). One T-cell receptor complex carries ten of them: three on each of its two zeta tails and one on each of its four CD3 tails.

A first test came in 1991, of whether the tail alone could signal. Irving and Weiss joined the outer and membrane-crossing parts of an unrelated protein, CD8, to the zeta tail. The hybrid could recognise no antigen, yet clustering it with an antibody set off the T cell’s activation signals. Other laboratories reported similar hybrids that year. The tail alone was enough.

The B-cell receptor follows the same plan: a membrane-bound antibody with a tail three amino acids long (in its IgM form), flanked by Ig-alpha and Ig-beta with one ITAM each. A Src-family kinase, mainly Lyn, phosphorylates the ITAM, and Syk, a relative of ZAP-70 below, reads it.

## The first minute: two phosphates, then three branches

So where is the kinase? It is already there. Lck is a Src-family tyrosine kinase (see [protein interaction modules](https://stemhop.com/lessons/protein-interaction-modules)) held to the inner face of the membrane by fatty acid chains, and in a resting T cell a good part of it is already active. A share of it also rides on the inner tail of a co-receptor, CD4 or CD8, which binds an unvarying part of the same major histocompatibility complex (MHC) protein the receptor is reading. So why is a resting T cell quiet? A phosphatase, CD45, keeps removing the phosphates Lck adds to the ITAMs. In one leading model, when the two cells press close, CD45, whose outer part is bulky, is pushed out of the contact, and phosphates build up on the engaged receptors. How triggering works is still debated.

In 1988 two groups (Rudd and colleagues, then Veillette and colleagues) reported that Lck comes out of broken-open T cells attached to CD4 and CD8. That did not show it was needed. Weiss’s laboratory had a mutant T-cell line with an intact receptor and no calcium response; the fault lay in its gene for Lck. In 1992 Straus and Weiss put an intact gene back, and the response returned.

The sequence:

1. **Lck phosphorylates both tyrosines of an ITAM.**
2. **ZAP-70 docks and is switched on.** ZAP-70 is a second tyrosine kinase, with two SH2 domains side by side, spaced to fit the two phosphotyrosines. It binds tightly only when both are phosphorylated, so one stray phosphate does not start a T cell. Docking opens ZAP-70, and Lck then phosphorylates it.
3. **ZAP-70 phosphorylates LAT**, a scaffold ([adaptors and scaffolds](https://stemhop.com/lessons/adaptors-and-scaffolds)) set in the membrane, whose tyrosines become SH2 docking sites.

*Figure (AI-generated illustration).* The receptor carries no enzyme. Lck, riding on a co-receptor that grips the same MHC protein, phosphorylates both tyrosines of an ITAM; ZAP-70 binds tightly only when both are phosphorylated, then phosphorylates the LAT scaffold, from which three branches leave: calcium, DAG and Ras. Image: two membranes, the presenting cell above and the T cell below. The receptor reads a peptide held on an MHC protein, and a co-receptor beside it grips the same MHC protein and carries Lck on its inner tail. On one partner-chain tail inside the T cell, an ITAM carries two phosphates, and the two lobes of ZAP-70 grip both phosphates of that one ITAM. An arrow runs from ZAP-70 to the LAT scaffold in the membrane, from which three arrows fan out to calcium, DAG and Ras.

Three branches leave LAT.

**Calcium to nuclear factor of activated T cells (NFAT).** PLC-gamma docks on LAT, is switched on by phosphorylation, and splits phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG) ([PLC, IP3, DAG and PKC](https://stemhop.com/lessons/plc-ip3-dag-pkc)). IP3 empties the calcium store, store-operated channels keep calcium high ([calcium signalling](https://stemhop.com/lessons/calcium-signaling)), and calmodulin switches on the phosphatase calcineurin. Calcineurin strips phosphates from the transcription factor NFAT, which then enters the nucleus ([the phosphorylation switch](https://stemhop.com/lessons/phosphorylation-switch)). The transplant drug cyclosporin works by blocking calcineurin.

**DAG to PKC to NF-κB.** DAG recruits protein kinase C, in T cells mainly the theta form, which leads through a scaffold complex to the IκB kinase and so to NF-κB (the lesson before this one).

**Ras to extracellular signal-regulated kinase (ERK).** Two exchange factors load Ras with GTP: SOS, brought to LAT by Grb2, and RasGRP, switched on by DAG. Raf, MAPK/ERK kinase (MEK) and ERK follow ([Ras to MAPK](https://stemhop.com/lessons/ras-to-mapk)), and ERK helps build the transcription factor AP-1.

NFAT, NF-κB and AP-1 meet on the control regions of genes such as the one for interleukin-2, a cytokine that drives T-cell division through a JAK-STAT receptor. In an experiment that triggered the receptor with a light-activated peptide, LAT was phosphorylated within 4 seconds and a calcium rise followed within 6 to 7 seconds (Huse and colleagues, 2007). The steps down to it use most of Units 2 to 4.

## One signal is not enough: the second signal and two brakes

Antigen receptors are varied almost at random, and some fit the body’s own peptides, so the receptor is not trusted to decide alone.

**Signal two.** For a T cell meeting its antigen for the first time, a second receptor, CD28, must bind a B7 protein (B7-1 or B7-2) on the cell presenting the peptide. Presenting cells display far more B7 once they have detected signs of infection. CD28 has no enzyme either: a tyrosine motif in its short tail, once phosphorylated, recruits PI 3-kinase ([PI 3-kinase, Akt and insulin](https://stemhop.com/lessons/pi3k-akt-insulin)) and Grb2. In the classic experiments on cultured T cells, signal one alone did worse than nothing: the cells entered a lasting unresponsive state called anergy.

*Figure (AI-generated illustration).* For a T cell meeting its antigen for the first time, signal one from the receptor is not trusted alone. CD28 must also bind a B7 protein, which presenting cells display once they have detected signs of infection. In the classic cultured-cell experiments, signal one alone left the cell in the lasting unresponsive state called anergy. Image: two panels, each a T cell facing a presenting cell. On the left, the T-cell receptor binds a peptide held on an MHC protein while CD28 has no partner, and the outcome box reads Anergy. On the right, CD28 also grips B7 on the presenting cell, two arrows run into the T cell, and the outcome box reads Activation.

**Brake one: CTLA-4.** An activated T cell puts up a further receptor, CTLA-4, a close relative of CD28 that binds the same B7 proteins. Regulatory T cells, a subset whose job is to restrain other T cells, carry CTLA-4 all the time. Measured on isolated proteins it binds B7 roughly ten times more tightly than CD28 does, and on a cell the gap is wider, because a CTLA-4 dimer grips two B7 molecules at once. It also pulls B7 off the presenting cell and takes it into the T cell to be destroyed (David Sansom’s laboratory, 2011).

Jeffrey Bluestone’s laboratory in 1994, and Matthew Krummel and James Allison in 1995, reported that an antibody blocking CTLA-4 increased T-cell responses in culture, as releasing a brake would. Mice made without CTLA-4, in the laboratories of Arlene Sharpe and of Tak Mak, died within a few weeks of birth, their lymphocytes multiplying unchecked. Much of this is the loss of CTLA-4 from regulatory T cells: removing it from those cells alone was enough to cause fatal autoimmunity in mice (Shimon Sakaguchi’s laboratory, 2008). They use it to take B7 away from presenting cells, so other T cells get less signal two.

**Brake two: PD-1.** Tasuku Honjo’s laboratory in Kyoto reported the gene for PD-1 (programmed death-1) in 1992. PD-1 also appears on activated T cells; its partner programmed death-ligand 1 (PD-L1) is displayed by many other cells and by many tumours. This brake works from the inside. When PD-L1 binds, two tyrosines on PD-1’s tail are phosphorylated, and the main one, in a motif called the ITSM, recruits SHP-2, a tyrosine phosphatase that removes phosphates the activating kinases have just added. In a membrane system rebuilt from purified proteins in 2017, the target SHP-2 reached most readily was CD28; work in T cells suggests the antigen receptor pathway is damped as well.

*Figure (AI-generated illustration).* Two brakes, simplified. CTLA-4 binds B7 more tightly than CD28 does and can remove it from presenting cells, reducing co-stimulation; regulatory T cells use this route. PD-1 brakes from inside: once PD-L1 binds, its phosphorylated tail, mainly the ITSM motif, recruits the phosphatase SHP-2, which removes phosphates from activating signalling proteins such as CD28 and components of the antigen-receptor pathway. The tail phosphates themselves are the docking site, not the target. Image: two schematic panels, titled CTLA-4: outside and PD-1: inside, each showing a T cell below a presenting cell. Left, CTLA-4 on the T cell reaches up and grips two B7 proteins on the presenting cell, while CD28, labelled weaker grip, reaches toward one B7 with a dotted line. Right, PD-1 on the T cell is bound to PD-L1 on another cell and has two phosphate circles on its tail; the phosphatase SHP-2 docks on those phosphates, and an arrow runs from SHP-2 to a phosphate on the tail of CD28, which is bound to B7 beside it, labelled SHP-2 removes CD28's phosphate.

Mice lacking PD-1 at first looked normal. Bred onto an inbred background and watched as they aged, they developed autoimmunity (an immune attack on the body’s own tissues) resembling lupus, reported in 1999. That is later and milder than the loss of CTLA-4.

## Releasing a brake to treat cancer

Many tumours carry altered proteins that T cells can recognise, and many display programmed death-ligand 1 (PD-L1). What happens if you block a brake instead of attacking the tumour? In 1996 Dana Leach, Krummel and Allison reported that mice given an antibody against CTLA-4 rejected tumours that grew in untreated mice. In 2002 the groups of Honjo and Nagahiro Minato reported that mice held tumours back better when PD-1 could not meet PD-L1.

The drugs are antibodies that cover a brake: ipilimumab for CTLA-4, approved in 2011 for advanced melanoma, a skin cancer, then nivolumab and pembrolizumab for PD-1 in 2014. None is aimed at the tumour cell. Each binds a receptor on the patient’s own T cells, and a response that was being shut down runs on. In mice, part of the CTLA-4 antibody’s effect also comes from removing regulatory T cells inside the tumour. Allison and Honjo shared the 2018 Nobel Prize.

The price is what the mice predicted. With a brake released, T cells also attack healthy tissue: inflammation of the gut, skin, liver and hormone glands is common, generally more so with CTLA-4 blockade. And many tumours do not respond at all.

## Building a receptor from parts

**Film transcript: Antibody Outside, Zeta Tail Inside**

### Film transcript: Antibody Outside, Zeta Tail Inside

The T cell receptor reads a short peptide held in the groove of an MHC protein. Blocking a brake helps only if the patient already has T cells that recognise the tumour. The other approach gives T cells a new receptor. Can you build one from parts? In 1989, Gideon Gross, Tova Waks and Zelig Eshhar joined the variable regions of an antibody to the constant regions of T cell receptor chains. T cells carrying the hybrid responded to the antibody's target. Yoshihisa Kuwana and colleagues had published the same kind of construct in 1987. The receptor's own tips read a peptide held on an MHC protein. An antibody is different. It grips a whole folded protein directly.

So such a receptor needs no peptide and no MHC protein. Later designs, from Eshhar's laboratory and others, were single chains. They put an antibody fragment outside the cell and the zeta tail inside. This is a chimeric antigen receptor, or CAR. Remember the plan: antibody outside, zeta tail inside.

Blocking a brake helps only if the patient already has T cells that recognise the tumour. The other approach gives T cells a new receptor.

In 1989 Gideon Gross, Tova Waks and Zelig Eshhar joined the variable regions of an antibody to the constant regions of T-cell receptor chains, and T cells carrying the hybrid responded to the antibody’s target. Yoshihisa Kuwana and colleagues had published the same kind of construct in 1987. An antibody binds its target on the cell surface directly, so such a receptor needs no peptide and no major histocompatibility complex (MHC) protein. Later designs, from Eshhar’s laboratory and others, were single chains: an antibody fragment outside and the zeta tail inside. This is a chimeric antigen receptor, or CAR.

### Design problem

Build a receptor that makes a T cell kill any cell that carries a surface protein of your choice. You may take parts from an antibody, from the T-cell receptor complex and from a co-stimulatory receptor. Say which part does the recognising, which gives the first signal and which gives the second. Then name one way your receptor could harm the patient.

> **One way to do it.** **Recognition.** Take the two variable regions of an antibody against your target and join them with a short linker into a single-chain fragment. Add a hinge and a membrane-crossing segment.
>
> **First signal.** Attach the zeta tail, with its three ITAMs. When the receptors cluster on a target cell, Lck phosphorylates the ITAMs and ZAP-70 docks. Much of the usual cascade follows, though a CAR’s signals are not identical to the T-cell receptor’s and depend less on LAT.
>
> **Second signal.** The first receptors of this kind stopped there, and in early cancer trials the cells often failed to multiply and persist: signal one without signal two. The fix, worked out by several groups including Michel Sadelain’s, was to add the cytoplasmic domain of a co-stimulatory receptor, CD28 or 4-1BB, to the same chain, so that one binding event delivers both signals.
>
> Carl June’s laboratory put such a receptor, aimed at the B-cell protein CD19, into the T cells of patients with leukaemia, a blood cancer. In 2011 it reported an adult in whom the cells multiplied more than a thousandfold.
>
> **The harm.** The receptor cannot tell a cancer cell from a healthy cell that carries the same protein. CD19 is on normal B cells too, so the treatment removes them and the patient may need antibodies supplied. A second risk: so many T cells fire at once that the cytokines they release, multiplied by the patient’s own macrophages, inflame the whole body.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/antigen-receptors-and-checkpoints/
